Can Lecanemab really slow Alzheimer's disease progression by eight years?

Recent real-world data suggests Lecanemab could delay progression by 8.3 years in specific patient groups, though further understanding of its impact on daily life is needed.

Why is Lecanemab not available on the NHS?

The NHS spending watchdog deemed Lecanemab's benefits too modest to justify its cost, although new data is prompting calls for reconsideration and trial access.

What is the role of amyloid protein in Alzheimer's disease?

Alzheimer's drugs like Lecanemab and Donanemab target amyloid, a protein that builds up in the brain, aiming to slow cognitive decline.

Home / Health / Alzheimer's Drug Offers 8-Year Delay, NHS Rejection Sparks Debate

Alzheimer's Drug Offers 8-Year Delay, NHS Rejection Sparks Debate

5 Dec

•

Summary

Lecanemab may delay Alzheimer's progression by 8.3 years.
Real-world data supports benefits beyond initial trial findings.
Calls grow for NHS trial access to the drug.

Alzheimer's Drug Offers 8-Year Delay, NHS Rejection Sparks Debate

Researchers have presented compelling real-world data suggesting that the Alzheimer's drug Lecanemab, currently not funded by the NHS, could delay disease progression by an impressive 8.3 years for eligible patients. This new information, shared at a dementia conference, indicates that the benefits might be more substantial than initial clinical trials suggested, prompting urgent calls for the UK government to consider trial access.

These findings have reignited debate surrounding Lecanemab's availability, with advocates arguing that patients who cannot afford private treatment are being left behind. The drug, also known as Leqembi, targets amyloid protein buildup in the brain. While the National Institute for Health and Care Excellence (Nice) previously deemed its benefits modest for the cost, this new data offers a more optimistic outlook.

Additionally, a more convenient injectable formulation of Lecanemab is being developed, which could simplify administration compared to the current IV infusion. Experts emphasize the need for early diagnosis to maximize the impact of such treatments, highlighting that over a third of dementia cases in the UK remain undiagnosed. The ongoing development of Alzheimer's therapies signals hope for improved patient outcomes.